Clinical Trials · NCT06441331

Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors

Name: Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

RecruitingPhase 1Octreotide

Phase: Phase 1
Recruitment status: Recruiting
Sponsor: ITM Solucin GmbH
Enrollment: 20
Start date: Sep 2025
Locations: 6 sites, 3 countries
Primary endpoint: Pediatric Dosage

View Octreotide compound reference